Company intelligence / Profile preview

Karos Pharmaceuticals

New Haven, Connecticut, United Statesnrc.gov ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Karos Pharmaceuticals was a privately held, clinical-stage biopharmaceutical company focused on developing small molecule therapeutics that modulate peripheral serotonin synthesis via TPH1 inhibition. Its lead program advanced to Phase 2 clinical trials targeting pulmonary arterial hypertension. The company also explored treatments for carcinoid syndrome and various fibrotic, inflammatory, and metabolic rare diseases. Karos was acquired in August of 2017.

Therapeutic areas: CardiovascularMetabolic DisordersImmunologyOncologyRare Diseases
Modalities: Small molecules (notably TPH1 inhibitors)
Industry: Biotech

Drug pipeline

1 asset

rodatristat ethyl

Phase 2

Indications: Pulmonary arterial hypertension, Carcinoid syndrome

Beyond the preview

Go deeper on Karos Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karos Pharmaceuticals.

Explore the full profile